Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen
about
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvStructure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 NeutralizationStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setCrystal Structure of the HIV-2 Neutralizing Fab Fragment 7C8 with High Specificity to the V3 Region of gp125Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected HumansCrystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2Primary and tertiary structures of the Fab fragment of a monoclonal anti-E-selectin 7A9 antibody that inhibits neutrophil attachment to endothelial cellsMode of binding of anti-P-glycoprotein antibody MRK-16 to its antigen. A crystallographic and molecular modeling studyBactericidal antibody recognition of meningococcal PorA by induced fit. Comparison of liganded and unliganded Fab structuresMulti-constraint computational design suggests that native sequences of germline antibody H3 loops are nearly optimal for conformational flexibilityThe tyrosine corner: a feature of most Greek key beta-barrel proteinsDetermining the invariant structure elements of the HIV-1 variable V3 loops: insight into the HIV-MN and HIV-Haiti isolates.3D structure model of the principal neutralizing epitope of Minnesota HIV-1 isolate.Dual spatial folds and different local structures of the HIV-1 immunogenic crown in various virus isolates.Conformational preferences of the HIV-1 principal neutralizing determinant.Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution.Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodiesFolding funnels and binding mechanisms.Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotypingHigh resolution structures of the 4-4-20 Fab-fluorescein complex in two solvent systems: effects of solvent on structure and antigen-binding affinityHuman monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins.Structure and immune recognition of trimeric pre-fusion HIV-1 Env.Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine seraA human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts.Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an AntibodyGenetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.Structure and polymorphism of HIV-1 third variable loops.Postentry neutralization of adenovirus type 5 by an antihexon antibody.Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving.A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints.Contribution of arginine residues in the RP135 peptide derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5beta HIV-1 neutralizing antibody.Variability analysis of HIV-1 gp120 V3 region: III. Distinctions between various sets of peptide fragments derived from the sequences belonging to different HIV-1 taxons.The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domainCoreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
P2860
Q24679395-BD6C0509-0C97-4BA9-A22E-2D7CA1AE982BQ27644383-BA43EE5A-DECF-4C97-80B8-253B233199CFQ27649247-8F2B4D77-5FD2-4260-8482-98F0C853FC12Q27650903-97ACE77C-AF36-443D-8A7A-B7128C781596Q27667679-3018C832-AE6B-4E2E-90D4-2CFC69F2DBFDQ27679123-53368C63-7CA8-4CEC-8647-CE85A197B380Q27731338-2D7553B1-18D2-405C-B6C2-C7EF5BE7FB34Q27756637-24511EC8-B211-414F-AC02-0633B3D4C6DCQ27765326-38315534-1129-4EB8-92A8-23BDB61AE81CQ27766459-DA7C765B-4200-4B1A-909A-AB0558C00D93Q28914723-E500556C-1C7B-4AAC-8BC3-CBEEED17A3EBQ30193951-49C5AF77-F77B-45D3-AE63-AD2C72110E09Q30370415-77C43C1E-3D46-4173-A4BA-405E223DDA64Q30886684-63A53166-D29F-420A-9317-765A3C5D857CQ30952700-96F50DB1-1125-4DE1-970E-4885056A84C8Q31010762-E4E772E4-F824-41F1-B8B2-A1F54BD1B68CQ31112947-ADD84EAC-50A7-49C1-89D5-F11EEC6306FDQ31911259-D1B8D32A-0ECC-4213-B633-B8EF3343F147Q32157115-AC12A87D-C9DB-4CCC-833D-403282EB08F2Q33639792-D4162609-EB2A-42D9-886F-02946EDF7E00Q33743626-8C70E7AD-6C49-4F5B-BE5F-B6C2DBA086B0Q33782134-20A2D12D-4636-4ACF-A3B2-1E6B027A781EQ34018972-9B3CEF4E-7FDB-4B72-80BA-BBEB4F70C4E1Q34145199-0E510DA2-9AB9-41DC-8F9E-08945D2A2CB7Q34867076-D1C71608-D704-4171-8949-E84A9E0D7811Q35142291-07094D39-A457-42DB-80F6-E1C0F433BB30Q35828529-03EA5839-DECA-4CE5-B378-FA49CC91F5C1Q35828898-B24FB3A4-E35B-4AB0-88CA-FFA3563F2A2AQ35837816-800F8E7C-42A4-4539-AEC6-DDA7EF47D51AQ35994354-C68AD84E-F51E-4310-B5FD-CC3D040343CAQ36433887-5B538F52-3106-40E3-AF76-C6F1266BC40FQ36509765-AC248E6A-1D9A-4BCD-9EFD-3AFE4315676EQ36798525-BEC7D0E9-D2D8-4DE5-984D-E5EF5FB99BD2Q37596703-FFE62E7C-E433-4A99-BC08-71B3E234D877Q38014473-8CBD2DE2-51ED-468B-A1B3-F34D54085257Q38315995-1A4D6F5D-7C5D-4327-A5F9-A51E050C8D70Q38356824-C9C8B0CD-37A2-4923-9932-B63E0D452CD3Q38554039-C497F93F-EE3E-4FC3-9242-5BB986AC0471Q39439112-44885C7F-467D-4862-A6FE-D4382CC5ECB6Q39578021-2EA74BBC-8A89-446F-A032-F71DCAA9DCD3
P2860
Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen
description
1993 nî lūn-bûn
@nan
1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Crystal structure of a human i ...... th its V3 loop peptide antigen
@ast
Crystal structure of a human i ...... th its V3 loop peptide antigen
@en
Crystal structure of a human i ...... th its V3 loop peptide antigen
@nl
type
label
Crystal structure of a human i ...... th its V3 loop peptide antigen
@ast
Crystal structure of a human i ...... th its V3 loop peptide antigen
@en
Crystal structure of a human i ...... th its V3 loop peptide antigen
@nl
prefLabel
Crystal structure of a human i ...... th its V3 loop peptide antigen
@ast
Crystal structure of a human i ...... th its V3 loop peptide antigen
@en
Crystal structure of a human i ...... th its V3 loop peptide antigen
@nl
P2093
P2860
P356
P1476
Crystal structure of a human i ...... th its V3 loop peptide antigen
@en
P2093
I A Wilson
P A Salinas
R L Stanfield
P2860
P304
P356
10.1073/PNAS.90.13.6325
P407
P577
1993-07-01T00:00:00Z